Vaccine development for bacterial pathogens: Advances, challenges and prospects

Trop Med Int Health. 2023 Apr;28(4):275-299. doi: 10.1111/tmi.13865. Epub 2023 Mar 22.

Abstract

The advent and use of antimicrobials have played a key role in treating potentially life-threatening infectious diseases, improving health, and saving the lives of millions of people worldwide. However, the emergence of multidrug resistant (MDR) pathogens has been a significant health challenge that has compromised the ability to prevent and treat a wide range of infectious diseases that were once treatable. Vaccines offer potential as a promising alternative to fight against antimicrobial resistance (AMR) infectious diseases. Vaccine technologies include reverse vaccinology, structural biology methods, nucleic acid (DNA and mRNA) vaccines, generalised modules for membrane antigens, bioconjugates/glycoconjugates, nanomaterials and several other emerging technological advances that are offering a potential breakthrough in the development of efficient vaccines against pathogens. This review covers the opportunities and advancements in vaccine discovery and development targeting bacterial pathogens. We reflect on the impact of the already-developed vaccines targeting bacterial pathogens and the potential of those currently under different stages of preclinical and clinical trials. More importantly, we critically and comprehensively analyse the challenges while highlighting the key indices for future vaccine prospects. Finally, the issues and concerns of AMR for low-income countries (sub-Saharan Africa) and the challenges with vaccine integration, discovery and development in this region are critically evaluated.

Keywords: antimicrobial resistant bacteria; bacterial vaccines; emerging vaccine technologies; infectious diseases; low- and middle-income countries; vaccines.

Publication types

  • Review

MeSH terms

  • Antigens
  • Bacteria
  • Humans
  • Vaccine Development
  • Vaccines* / therapeutic use

Substances

  • Vaccines
  • Antigens